Solvonis Therapeutics PLC (LSE:SVNS), the LSE-listed biopharmaceutical company focused on central nervous system disorders, has been granted a US patent covering a series of compounds from its post-traumatic stress disorder (PTSD) drug discovery programme.
The patent, granted by the United States Patent and Trademark Office, is a composition-of-matter patent.
This means it protects the underlying compounds themselves rather than only their method of use or manufacture, generally considered the strongest form of intellectual property protection in drug development.
The compounds are designed to modulate serotonin, dopamine and noradrenaline transporter systems, a mechanism known as monoamine modulation.
The grant follows a patent allowance announced in January 2026 and comes after Solvonis selected SVN-114 as its lead candidate from the programme.
PTSD affects more than 20 million people across the UK, US and major European markets, with few approved pharmaceutical treatments available.
Chief executive Anthony Tennyson pointed to Otsuka Pharmaceutical's agreement to acquire Transcend Therapeutics for up to $1.225 billion as evidence of growing commercial interest in next-generation PTSD therapies.
Solvonis said the patent forms part of a broader chemistry portfolio being built around the programme, providing flexibility for future development beyond SVN-114.